Efficacy and Safety of a Novel Paclitaxel-Nano-Coated Balloon for Femoro-Popliteal Angioplasty: 1-Year Results of EffPac Trial
DOI: 10.4244/EIJ-D-19-00292
Main Authors:
Ulf Teichgräber1, ; Thomas Lehmann2, ; René Aschenbach3, ; Dierk Scheinert4, ; Thomas Zeller5, ; Klaus Brechtel6, ; Erwin Blessing7, ; Michael Lichtenberg8, ; Sebastian Sixt9, ; Steffen Brucks10, ; Ulrich Beschorner11, ; Christof Tobias Klumb12, ; Markus Thieme13, ;
Collaborators:
Peter von Flotow14, ; Britta Heilmeier15, ; Christian Erbel16, ; Michael Werk17, ; Vicenç Riambau18, ; Andreas Wienke19, ;
1. University Hospital Jena, Department of Radiology, Am Klinikum 1, Jena, Germany, Germany 2. University Hospital Jena, Center for Clinical Studies, Jena, Germany 3. University Hospital Jena, Department of Radiology, Am Klinikum 1, Jena, Germany 4. University Hospital Leipzig, Department of Angiology, Liebigstraße 20, Leipzig, Germany 5. Heart Center Bad Krozingen, Südring 15, Bad Krozingen, Germany 6. Ihre-Radiologen Berlin Radiology Associates, Budapester Str. 15-19, Berlin, Germany 7. SRH Clinic Karlsbad- Langensteinbach, Guttmannstr. 1, Karlsbad, Germany 8. Clinic of Angiology Arnsberg, Stolte Ley 5, Arnsberg, Germany 9. Angiologikum Hamburg, Wördemanns Weg 25-27, Hamburg, Germany 10. Angiologikum Hamburg, Wördemanns Weg 25-27, Hamburg, Germany 11. Heart Center Bad Krozingen, Südring 15, Bad Krozingen, Germany 12. University Hospital Jena, Department of Radiology, Am Klinikum 1, Jena, Germany; Army Hospital Bundeswehrkrankenhaus Ulm, Radiology Department VIII, Oberer Eselsberg 40, Ulm, Germany 13. REGIOMED Clinics GmbH, MedinosClinics LK Sonneberg GmbH, Abt. Angiology/Cardiology/Diabetology, Neustadter Str. 61, Sonneberg, Germany. 14. Department Vascular Medicine, Westpfalz-Hospital, Kusel, Germany 15. Center Internal Medicine, Ruprecht-Karls-University Heidelberg, Germany. 16. Center Internal Medicine, Ruprecht-Karls-University Heidelberg, Germany. 17. Martin-Luther-Hospital, Berlin, Germany. 18. Hospital Clínic de Barcelona, Barcelona, Spain. 19. Medical Epidemiology, Martin-Luther- University Halle, Germany
Disclaimer:
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.
Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.
Aims:-Although paclitaxel drug-coated balloon (DCB) angioplasty is an established endovascular treatment for peripheral artery disease, restenosis remains a major concern. Thus, we compared a novel paclitaxel-coated DCB with nano-coating technology with uncoated plain-old balloon angioplasty (POBA).
Methods and results:- This multicenter trial randomly assigned 171 patients with stenotic and occlusive lesions of the femoropopliteal artery to angioplasty with the novel DCB or uncoated POBA. The primary endpoint late lumen loss at 6 months was 0.92 mm lower in the DCB group (95%CI: -1.36 mm; -0.49 mm, P<0.001). Patients showed improved walking after DCB treatment at 6 months (P=0.021). In the DCB group, 44.6%/50% of the patients improved by three Rutherford-Becker classification stages after 6/12 months (POBA: 27.8%/36.8%). Only one patient needed TLR (1.3%) in the DCB group, compared to 14 (18.7%) in the POBA group after 12 months (relative risk [RR]=0.08, 95%CI: 0.01; 0.53, P<0.001). Primary patency was 90.3% (DCB group) vs. 65.3% (POBA group) after 12 months (RR=1.38, 95%CI: 1.14; 1.67, P<0.001).
Conclusions:- The novel DCB was effective and safe for inhibiting restenosis. Moreover, it demonstrated a better improvement in walking than POBA and showed no mortality concerns due to paclitaxel application after 12 months.
